跳至主要内容
临床试验/NL-OMON49946
NL-OMON49946尚未招募3 期

A randomized, double blinded clinical trial of convalescent plasma compared to standard plasma for treatment of hospitalized non-IC patients with COVID-19 infections - COV-PLAS

eids Universitair Medisch Centrum0 个研究点目标入组 430 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
尚未招募
入组人数
430

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • 1. Maximal 3 days hospitalized patients at plasma infusion.
  • 2. Age * 18 years and * 85 years
  • 3. SARS-CoV-2 infection: confirmed by PCR (BAL, sputum, nasal and/or pharyngeal
  • 4. Symptoms not expected to lead to IC transfer within 6 hours of first plasma
  • administration
  • 5. Written informed consent including storing of specimen for future testing

排除标准

  • 1. Accompanying diseases other than COVID-19 with an expected survival time of
  • less than 12 months
  • 2. Chronic obstructive lung disease (COPD), stage 4
  • 3. Lung fibrosis with UIP pattern in CT und Severe emphysema
  • 4. Chronic heart failure NYHA >= 3 and/or pre-existing reduction of left
  • ventricular ejection fraction to * 30%
  • 5. Cardiovascular failure requiring diuretics
  • 6. Signs of severe coagulopathy : thrombocytopenia a/o prolongation of the
  • PT/INR, PTT a/o elevation of D-dimer, a/o decreased fibrinogen level waardes ?
  • 7. Liver cirrhosis Child C
  • 8. Liver failure: Bilirubin > 5xULN and elevation of ALT /AST (at least one
  • 9. Any history of severe adverse reactions to plasma proteins
  • 10. Known deficiency of immunoglobulin A
  • 11. Pregnancy
  • 12. Breastfeeding women
  • 13. Volume overload until sufficiently treated
  • 14. Pulmonary edema
  • 15. Participation in another clinical trial for treatment of COVID-19
  • 16. Psychiatric or cognitive illness or recreational drug/alcohol use that in
  • the opinion of the principal investigator, would affect subject safety and/or

研究者

相似试验